dbo:abstract
|
- BNC210 (also known as IW-2143 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor, by Bionomics Limited. It is currently being investigated for the treatment of post traumatic stress disorder. The drug has demonstrated clinically significant anxiety reduction in both animal models and in Phase I trials. It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models. Phase I trials have shown no serious side effects. Bionomics previously licensed it to Ironwood Pharmaceuticals in January 2012, where it was known as IW-2143. In December 2012, IW-2143 begun undergoing phase I clinical trials in the United States, but in November 2014, was released back to Bionomics in a mutual agreement. Bionomics will now continue development and clinical testing, with Ironwood receiving a royalty for their work done. In April 2015, BNC210 was in phase II clinical trials. The estimated study completion date was September 2018. In October 2018, the company announced that the candidate failed to meet its primary endpoint in treating PTSD but may have shown some anti-depressant and anxiolytic effects (the phase II trial's secondary endpoints). The drug is still being developed and secured Fast Track designation from the FDA based on the drug's novel mechanism of action and the 'large unmet need with PTSD' in the community. There is a large unmet need for efficacious anxiolytics which do not have the habituation, dependency, sedation, tolerance, and intoxication issues with current generation anxiolytics. (en)
|
dbo:casNumber
| |
dbo:fdaUniiCode
| |
dbo:pubchem
| |
dbo:thumbnail
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 10819 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:atcPrefix
| |
dbp:c
| |
dbp:casNumber
| |
dbp:chemspiderid
| |
dbp:h
| |
dbp:iupacName
|
- (L)-Isoleucyl-(L)-tryptophan (en)
|
dbp:legalStatus
| |
dbp:n
| |
dbp:o
| |
dbp:pubchem
| |
dbp:smiles
| |
dbp:stdinchi
| |
dbp:stdinchikey
|
- BVRPESWOSNFUCJ-LKTVYLICSA-N (en)
|
dbp:unii
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
rdf:type
| |
rdfs:comment
|
- BNC210 (also known as IW-2143 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor, by Bionomics Limited. It is currently being investigated for the treatment of post traumatic stress disorder. The drug has demonstrated clinically significant anxiety reduction in both animal models and in Phase I trials. It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models. (en)
|
rdfs:label
| |
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:depiction
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |